Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,653 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
Oki R, Izumi Y, Fujita K, Miyamoto R, Nodera H, Sato Y, Sakaguchi S, Nokihara H, Kanai K, Tsunemi T, Hattori N, Hatanaka Y, Sonoo M, Atsuta N, Sobue G, Shimizu T, Shibuya K, Ikeda K, Kano O, Nishinaka K, Kojima Y, Oda M, Komai K, Kikuchi H, Kohara N, Urushitani M, Nakayama Y, Ito H, Nagai M, Nishiyama K, Kuzume D, Shimohama S, Shimohata T, Abe K, Ishihara T, Onodera O, Isose S, Araki N, Morita M, Noda K, Toda T, Maruyama H, Furuya H, Teramukai S, Kagimura T, Noma K, Yanagawa H, Kuwabara S, Kaji R; Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) Collaborators. Oki R, et al. Among authors: nishiyama k. JAMA Neurol. 2022 Jun 1;79(6):575-583. doi: 10.1001/jamaneurol.2022.0901. JAMA Neurol. 2022. PMID: 35532908 Free PMC article. Clinical Trial.
Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis.
Aizawa H, Kato H, Oba K, Kawahara T, Okubo Y, Saito T, Naito M, Urushitani M, Tamaoka A, Nakamagoe K, Ishii K, Kanda T, Katsuno M, Atsuta N, Maeda Y, Nagai M, Nishiyama K, Ishiura H, Toda T, Kawata A, Abe K, Yabe I, Takahashi-Iwata I, Sasaki H, Warita H, Aoki M, Sobue G, Mizusawa H, Matsuyama Y, Haga T, Kwak S. Aizawa H, et al. Among authors: nishiyama k. J Neurol. 2022 Feb;269(2):885-896. doi: 10.1007/s00415-021-10670-y. Epub 2021 Jun 30. J Neurol. 2022. PMID: 34191081 Free PMC article. Clinical Trial.
Cognitive and behavioral status in Japanese ALS patients: a multicenter study.
Watanabe Y, Raaphorst J, Izumi Y, Yoshino H, Ito S, Adachi T, Takigawa H, Masuda M, Atsuta N, Adachi Y, Isose S, Arai K, Yokota O, Oda M, Ogino M, Ichikawa H, Hasegawa K, Kimura H, Shimizu T, Aiba I, Yabe H, Kanba M, Kusumi K, Aoki T, Hiroe Y, Watanabe H, Nishiyama K, Nomoto M, Sobue G, Beeldman E, Hanajima R, Nakashima K; ALS-FTD-Q-J research group. Watanabe Y, et al. Among authors: nishiyama k. J Neurol. 2020 May;267(5):1321-1330. doi: 10.1007/s00415-019-09655-9. Epub 2020 Jan 18. J Neurol. 2020. PMID: 31955246
Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K, Izumi Y, Banno H, Uozumi R, Morita S, Egawa N, Ayaki T, Nagai M, Nishiyama K, Watanabe Y, Hanajima R, Oki R, Fujita K, Takahashi N, Ikeda T, Shimizu A, Morinaga A, Hirohashi T, Fujii Y, Takahashi R, Inoue H. Imamura K, et al. Among authors: nishiyama k. BMJ Open. 2019 Dec 2;9(12):e033131. doi: 10.1136/bmjopen-2019-033131. BMJ Open. 2019. PMID: 31796494 Free PMC article.
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial.
Kuwabara S, Mori M, Misawa S, Suzuki M, Nishiyama K, Mutoh T, Doi S, Kokubun N, Kamijo M, Yoshikawa H, Abe K, Nishida Y, Okada K, Sekiguchi K, Sakamoto K, Kusunoki S, Sobue G, Kaji R; Glovenin-I CIDP Study Group. Kuwabara S, et al. Among authors: nishiyama k. J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):832-838. doi: 10.1136/jnnp-2017-316427. Epub 2017 Aug 2. J Neurol Neurosurg Psychiatry. 2017. PMID: 28768822 Free PMC article. Clinical Trial.
Pitfalls in clinical diagnosis of anti-NMDA receptor encephalitis.
Kaneko A, Kaneko J, Tominaga N, Kanazawa N, Hattori K, Ugawa Y, Moriya A, Kuzume D, Ishima D, Kitamura E, Nishiyama K, Iizuka T. Kaneko A, et al. Among authors: nishiyama k. J Neurol. 2018 Mar;265(3):586-596. doi: 10.1007/s00415-018-8749-3. Epub 2018 Jan 22. J Neurol. 2018. PMID: 29356973
Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome.
Yamagishi Y, Kuwahara M, Suzuki H, Sonoo M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida KI, Mutoh T, Yamasaki R, Takashima H, Matsui M, Nishiyama K, Sobue G, Kusunoki S. Yamagishi Y, et al. Among authors: nishiyama k. J Neurol Neurosurg Psychiatry. 2020 Dec;91(12):1339-1342. doi: 10.1136/jnnp-2020-323960. Epub 2020 Oct 11. J Neurol Neurosurg Psychiatry. 2020. PMID: 33041261
Japanese version of the ALS-FTD-Questionnaire (ALS-FTD-Q-J).
Watanabe Y, Beeldman E, Raaphorst J, Izumi Y, Yoshino H, Masuda M, Atsuta N, Ito S, Adachi T, Adachi Y, Yokota O, Oda M, Hanashima R, Ogino M, Ichikawa H, Hasegawa K, Kimura H, Shimizu T, Aiba I, Yabe H, Kanba M, Kusumi K, Aoki T, Hiroe Y, Watanabe H, Nishiyama K, Nomoto M, Sobue G, Nakashima K; ALS-FTD-Q-J Research Group. Watanabe Y, et al. Among authors: nishiyama k. J Neurol Sci. 2016 Aug 15;367:51-5. doi: 10.1016/j.jns.2016.05.036. Epub 2016 May 18. J Neurol Sci. 2016. PMID: 27423564
A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS).
Yamaguchi N, Misawa S, Sato Y, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kohara N, Hirata K, Nishiyama K, Yabe I, Kaida KI, Suzuki N, Nodera H, Tsuji S, Koike H, Kira JI, Hanaoka H, Kusunoki S, Kuwabara S; JET-GBS Group. Yamaguchi N, et al. Among authors: nishiyama k. JMIR Res Protoc. 2016 Nov 7;5(4):e210. doi: 10.2196/resprot.6610. JMIR Res Protoc. 2016. PMID: 27821382 Free PMC article.
[Role of the liaison officer in disaster countermeasures implemented by the Japanese Society of Neurology: Hope for the best and prepare for the worst].
Nakane S, Mizoguchi K, Abe K, Atsuta N, Iguchi Y, Ikeda Y, Kaji R, Kamei S, Kitagawa K, Kimura K, Suzuki M, Takashima H, Terayama Y, Nishiyama K, Furuya H, Matsubara E, Muramatsu SI, Yamamura O, Takeda A, Ito H; Committee for Measures Against Disaster, Japanese Society of Neurology. Nakane S, et al. Among authors: nishiyama k. Rinsho Shinkeigaku. 2020 Oct 24;60(10):643-652. doi: 10.5692/clinicalneurol.cn-001493. Epub 2020 Aug 20. Rinsho Shinkeigaku. 2020. PMID: 32814728 Japanese.
1,653 results